Pulsatile Oxytocin Administration Hypothesized to Reduce Myometrial Desensitization In-vitro, Potentially Lowering PPH Risk

Postpartum hemorrhage (PPH) is a leading cause of maternal mortality, primarily due to poor uterine muscle (myometrium) tone after delivery. Oxytocin is the first-line agent for PPH prevention and treatment, but continuous intravenous infusions for labor augmentation carry risks like hyperstimulation and can lead to myometrial desensitization. This desensitization increases the risk of PPH, highlighting a critical gap in optimizing oxytocin delivery to maintain uterine contractility and sensitivity.

This in-vitro study investigates the effect of pulsatile versus continuous oxytocin administration on human myometrial desensitization. Myometrial strips will be exposed to either continuous oxytocin or pulsatile oxytocin delivery. After 2 hours, solutions will be drained, and strips washed. Following a 30-minute PSS exposure, strips will be re-exposed to 10-7 oxytocin for 10 minutes to assess residual contractility and sensitivity. The primary endpoint is the comparison of myometrial desensitization between the two administration methods.

This abstract describes a proposed investigation and its underlying hypothesis, rather than presenting completed results. The investigators hypothesize that myometrial desensitization following pulsatile oxytocin exposure will be significantly lower compared to continuous oxytocin exposure. The study aims to establish whether myometrial contractility and sensitivity to oxytocin can be better preserved through pulsatile delivery for labor induction and augmentation. This preservation is expected to ultimately result in a reduced incidence of PPH. The research seeks to provide foundational data to support the clinical benefits of pulsatile oxytocin delivery, which has previously shown similar uterine contractility with less total oxytocin required in labor induction/augmentation, but without PPH as a primary outcome.